Company news
Alphamab Oncology news in 2026
Alphamab Oncology's news releases, calls and decks from 2026, newest first.
Next Day Disclosure Return
November 5, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 5, 2026
Next Day Disclosure Return
November 3, 2026
Next Day Disclosure Return
November 2, 2026
Voluntary announcement - IND approval by the FDA for a phase I clinical study of JSKN021
November 1, 2026
Supplementary announcement on discloseable transaction
October 29, 2026
Voluntary announcement - first patient dosed in phase III clinical study of JSKN033 monotherapy for the treatment of cervical cancer
October 28, 2026
Grant of award shares under the restricted share award scheme
October 27, 2026
Voluntary announcement - latest research updates of JSKN003 presented at the 2026 ESMO congress
October 26, 2026
Voluntary announcement - results of a phase I/II clinical study of JSKN033 in patients with CC following failure of standard treatment were presented at the 2026 esmo congress as a rapid oral presentation
October 26, 2026
Voluntary announcement - latest research results of two phase III clinical studies of anbenitamab (KN026) were presented at the 2026 ESMO Congress as lba oral presentations
October 26, 2026
Discloseable transaction - exercise of warrant to subscribe for preferred stock of pathos AI, inc.
October 23, 2026
Next Day Disclosure Return
October 22, 2026
Next Day Disclosure Return
October 15, 2026
Next Day Disclosure Return
October 14, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 5, 2026
Next Day Disclosure Return
September 28, 2026
2026 Interim report
September 24, 2026
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
April 22, 2026
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
April 22, 2026
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
April 1, 2026
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
March 26, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
March 23, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
March 19, 2026
Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer
March 18, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
March 16, 2026
Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE
March 12, 2026
Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer
March 10, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003
February 14, 2026
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology
January 26, 2026